Overview
“In China, we have moved from single-asset–focused agreements to a collaborative model aimed at leveraging the country’s ability to accelerate clinical trials in a highly competitive environment. Chinese healthcare groups, for their part, are looking to use the phase III development, regulatory approval capabilities, and commercial strength of international pharmaceutical companies to subsequently bring their treatments to the US market.”
Read the full commentary with Emmanuelle Trombe in Pharmaceutiques (in French via paywall) here.